The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Pfizer should partner with Sanofi

It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi

ALSO NOTED: Most patients don't respond to breast cancer drug; Germans investigating Bayer for aspirin price-fixing;

> Most women with breast cancer don't respond to the common chemo drug Taxol, according to a new study from the University of Texas M.D. Anderson Cancer Center--but the 15 percent to 20 percent

ALSO NOTED: Cosmo inks deal; GenMab expands cancer program; OPKO acquires rights Phase III drug; and much more...

> Italy's Cosmo Pharmaceuticals will pick up a €2 million upfront fee after inking a global licensing deal with Ferring for a reformulated budesonide product. Cosmo also could receive up to

Pfizer-Sanofi match not made in heaven?

Say the Pfizer/Sanofi-Aventis rumors are true: Would merging with the French drug maker boost

ALSO NOTED: Visiomed, Clinical Cell Culture to merge; Genzyme wants to reopen merger vote; Vical touts adjuvant data; and much

> Visiomed Group and Clinical Cell Culture are merging into a $27 million biotech company.

Sanofi stock up on Pfizer buyout talk

Sanofi-Aventis stock spiked this morning after rumors of a Pfizer buyout sparked a flurry of trading. The oil company Total does own 13 percent of Sanofi, and it has been looking to offload those

Pfizer tops the charts in global R&D spending

It hasn't had a lot to show for it so far, but Pfizer became the world's number one spender on research and development last year, grabbing the top spot from Ford. The list, assembled by the

Merck cautiously upbeat on cholesterol drug

Merck is looking to succeed where Pfizer so spectacularly failed. Merck presented positive Phase II data for its CTEP inhibitor

Pfizer top R&D spender worldwide

Hey, big spenders: Pfizer shelled out more on R&D last year than any other company in the world, and drug makers in general have stepped up their research budgets, the European Commission says.

SPOTLIGHT: Pfizer top R&D spender worldwide

Pfizer shelled out more on R&D last year than any other company in the world, and drugmakers in general have stepped up their research budgets, the European Commission says. Pfizer spent $8.18